Table 2.

Survival analysis for patients who received VBT or EBRT ± VBT in the three HIR groups.

Cohorts		RT Mode	5-Year OS	5-Year DFS	5-Year DMFS	5-Year LRFS
GOG-249	Full cohort	VBT	93.30%	84.20%	87.90%	89.00%
		EBRT ± VBT	91.50%	87.40%	87.70%	92.20%
		P	0.831	0.403	0.748	0.156
	After matching	VBT	93.80%	84.50%	88.40%	89.40%
		EBRT ± VBT	91.90%	84.60%	85.30%	91.20%
		P	0.855	0.834	0.855	0.311
PORTEC-2	Full cohort	VBT	96.00%	93.50%	92.50%	91.10%
		EBRT ± VBT	91.90%	88.70%	93.50%	94.50%
		P	0.586	0.331	0.745	0.375
	After matching	VBT	96.00%	88.70%	92.50%	91.10%
		EBRT ± VBT	96.40%	95.10%	95.10%	97.10%
		P	0.976	0.186	0.462	0.174
ESMO-ESGO-ESTRO	Full cohort	VBT	96.90%	87.40%	90.60%	89.20%
		EBRT ± VBT	93.10%	90.60%	91.20%	94.60%
		P	0.372	0.263	0.937	0.223
	After matching	VBT	96.90%	87.40%	91.20%	89.20%
		EBRT ± VBT	94.30%	91.10%	91.00%	95.90%
		P	0.489	0.233	0.850	0.170